OCTOBER 2023
Pulsed Field Ablation (PFA) is rapidly gaining traction as a cornerstone modality in the interventional treatment of atrial fibrillation (AF). Although the past decade witnessed substantial evolutionary strides in catheter ablation techniques, long-term clinical efficacy outcomes fell short of absolute success. The introduction of pulsed field ablation fundamentally transformed the therapeutic approach to the atrial myocardium. Traditional modalities, such as radiofrequency (RF) and cryoballoon ablation, relied on thermal energy (heating or cooling) to induce tissue necrosis around the pulmonary veins—the primary triggers of atrial fibrillation. Conversely, PFA delivers ultra-rapid, high-voltage electrical pulses that induce irreversible electroporation of the cardiomyocyte membrane, leading to targeted electrical isolation. This non-thermal approach ensures lasting lesion durability, streamlines more extensive myocardial ablation, and, above all, delivers an exceptional safety profile by leaving adjacent non-cardiac structures completely unaffected. As a frontrunner in electrophysiology, the Heart Rhythm Center (HRC) has actively advanced this innovative clinical workflow since 2022, demonstrating outstanding success in both acute procedural endpoints and long-term patient follow-up. Receiving the prestigious Gold Award at the Healthcare Business Awards 2023 serves as a testament to our commitment to clinical excellence, further inspiring our team to advance our clinical and translational research endeavors.
